Security
Semnur Pharmaceuticals, Inc. Warrant 01/01/2099 · SMNRW
SMNRWOTCWarrantCurrentCIK 1913577Updated Nov 6, 2026
Name history
Denali Capital Acquisition Corp. · through Sep 23, 2025
SMNRW price & chart
Loading TradingView…
OTC:SMNRW on TradingView ↗About the company
Semnur is a clinical late-stage specialty pharmaceutical company focused on the development and commercialization of novel non-opioid pain therapies. Semnur’s product candidate, SP-102 (SEMDEXA™), is the first non-opioid novel gel formulation administered epidurally in development for patients with moderate to severe chronic radicular pain/sciatica. Semnur is headquartered in Palo Alto, California.
In the news
No coverage from other publishers is available.
Seeking Alpha
Recent filings
10-Q filing
10-Q filing
424B3 filing
Entry into a Material Definitive Agreement · Unregistered Sales of Equity Securities · Regulation FD Disclosure
Items 1.01, 3.02, 7.01, 9.01
424B3 filing
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 774,000Source | 8,924,547Source | 1,943,000Source | 562,462Source | 52,115,789Source | 1,969,000Source | 9,147,903Source | 51,347,261Source | 1,346,000Source | 9,037,873Source | 50,687,403Source | 86,279,436Source |
| Property, Plant and Equipment, NetUSD | 689,000Source | — | 750,000Source | — | — | 750,000Source | — | — | 750,000Source | — | — | — |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 85,000Source | — | 39,000Source | — | — | 103,000Source | — | 1,013Source | 20,000Source | — | 204,464Source | — |
| Assets, CurrentUSD | 85,000Source | 35,428Source | 1,193,000Source | 14,144Source | 43,783Source | 1,219,000Source | 2,736Source | 65,412Source | 596,000Source | 16,868Source | 209,440Source | 907,836Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 15,367,000Source | 9,481,571Source | 31,616,000Source | 11,156,451Source | 9,206,623Source | 27,295,000Source | 10,739,217Source | 8,887,007Source | 22,096,000Source | 10,434,584Source | 8,491,480Source | 4,179,141Source |
| Stockholders’ equity: | ||||||||||||
| Preferred Stock, Value, IssuedUSD | 1,000Source | — | 1,000Source | — | — | 1,000Source | — | — | 1,000Source | — | — | 0Source |
| Common Stock, Value, IssuedUSD | 23,000Source | — | 23,000Source | — | — | 23,000Source | — | — | 23,000Source | — | — | — |
| Additional Paid in CapitalUSD | 255,025,000Source | — | 255,026,000Source | — | — | 255,026,000Source | — | — | 255,026,000Source | — | — | 0Source |
| Retained Earnings (Accumulated Deficit)USD | -269,642,000Source | -9,446,400Source | -284,723,000Source | -11,142,564Source | -9,163,097Source | -280,376,000Source | -10,736,738Source | -8,821,852Source | -275,800,000Source | -10,417,973Source | -8,282,297Source | -3,271,562Source |
| Stockholders' Equity Attributable to ParentUSD | -14,593,000Source | -42,008,000Source | -29,673,000Source | -44,448,000Source | -9,162,840Source | -25,326,000Source | -43,449,000Source | -8,821,595Source | -20,750,000Source | -10,417,716Source | -8,282,040Source | -3,271,305Source |
| Liabilities and EquityUSD | 774,000Source | 8,924,547Source | 1,943,000Source | 562,462Source | 52,115,789Source | 1,969,000Source | 9,147,903Source | 51,347,261Source | 1,346,000Source | 9,037,873Source | 50,687,403Source | 86,279,436Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 10,032,000Source | 6,594,071Source | 10,672,000Source | 8,268,951Source | 6,319,123Source | 10,380,000Source | 7,851,717Source | 5,999,507Source | 10,168,000Source | 7,547,084Source | 5,603,980Source | 1,291,641Source |
| Accounts Payable, CurrentUSD | 4,288,000Source | — | 6,918,000Source | — | — | 6,423,000Source | — | — | 5,912,000Source | — | — | — |
| Additional Financial Items | ||||||||||||
| Accrued Liabilities, CurrentUSD | 1,266,000Source | — | 1,647,000Source | — | — | 1,190,000Source | — | — | 739,000Source | — | — | — |
| Dividends PayableUSD | 0Source | — | 0Source | — | — | 0Source | — | — | 0Source | — | — | — |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 1,484,000Source | 92,000Source | 142,435,000Source | — | — | — |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts PayableUSD | — | — | — | — | — | — | 511,000Source | 0Source | 2,145,000Source | — | — | — |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -2,670,000Source | -399,000Source | -5,867,000Source | -753,296Source | -632,783Source | -426,095Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | — | — | — | 43,425,328Source | 39,711,908Source | -84,150,000Source |
| Cash flows from financing activities: | ||||||||||||
| Payments for Repurchase of Common StockUSD | — | — | — | — | — | — | — | — | — | 43,425,328Source | 40,536,908Source | — |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | 2,753,000Source | 394,000Source | 5,875,000Source | -42,859,628Source | -39,694,408Source | 85,395,842Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | — | — | — | — | — | 819,747Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 85,000Source | 13,000Source | 39,000Source | 55,000Source | 103,000Source | 7,000Source | 20,000Source | 16,868Source | 204,464Source | 819,747Source |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | 140,192,000Source | 152,000Source | 1,295,000Source | 119,000Source | 1,484,000Source | 92,000Source | 142,435,000Source | — | — | — |
| DepreciationUSD | — | — | 0Source | 0Source | — | — | 0Source | 0Source | 0Source | — | — | — |
| Dividends PayableUSD | — | — | 0Source | — | 0Source | — | 0Source | — | 0Source | — | — | — |
| General and Administrative ExpenseUSD | — | — | 151,451,000Source | 1,065,000Source | 2,975,000Source | 497,000Source | 3,310,000Source | 478,000Source | 157,870,000Source | — | — | — |
| Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 0Source | — | — | — |
| InterestExpenseNonoperatingUSD | — | — | — | 25,188Source | 123,000Source | 0Source | — | 26,974Source | — | 96,242Source | — | — |
| Investment Income, InterestUSD | — | — | — | 197,278Source | — | 18,080Source | — | 78,971Source | — | 1,578,042Source | 3,843,271Source | 1,221,600Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -152,594,000Source | -1,298,000Source | -4,347,000Source | -999,000Source | -4,576,000Source | -665,000Source | -160,416,000Source | -167,306Source | 632,536Source | -419,390Source |
| Operating Costs and ExpensesUSD | — | — | — | 212,951Source | — | 374,857Source | — | 246,600Source | — | 1,649,106Source | 3,173,826Source | — |
| Operating ExpensesUSD | — | — | 152,594,000Source | 1,298,000Source | 4,224,000Source | 999,000Source | 4,576,000Source | 665,000Source | 160,416,000Source | — | — | — |
| Payments to Acquire InvestmentsUSD | — | — | — | — | — | — | — | — | — | — | 825,000Source | — |
| Nonoperating Income (Expense) | — | — | — | — | —Source | —Source | — | — | — | — | — | — |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Income (Loss)USD | — | — | -152,594,000Source | -1,298,000Source | -4,224,000Source | -999,000Source | -4,576,000Source | -665,000Source | -160,416,000Source | -1,649,106Source | — |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | — | — | — | — | — | — | 0Source | — | — |
| Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 0Source | — | — |
| Net Income (Loss) Attributable to ParentUSD | — | — | -152,594,000Source | -1,298,000Source | -4,347,000Source | -999,000Source | -4,576,000Source | -665,000Source | -160,416,000Source | -167,306Source | 632,536Source |
| Earnings Per Share, BasicUSD per share | — | — | -0.76Source | -0.01Source | -0.02Source | -0.01Source | -0.02Source | -0.01Source | -0.78Source | — | — |
| Earnings Per Share, DilutedUSD per share | — | — | -0.76Source | -0.01Source | -0.02Source | -0.01Source | -0.02Source | -0.01Source | -0.78Source | — | — |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 201,686,617Source | 200,000,000Source | 230,209,142Source | 200,000,000Source | 230,209,142Source | 200,000,000Source | 204,784,615Source | — | — |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 201,686,617Source | 200,000,000Source | 230,209,142Source | 200,000,000Source | 230,209,142Source | 200,000,000Source | 204,784,615Source | — | — |
| Interest Expense (non-operating)USD | — | — | — | 25,188Source | 123,000Source | 0Source | — | 26,974Source | — | 96,242Source | — |
| Additional Financial Items | |||||||||||
| General and Administrative ExpenseUSD | — | — | 151,451,000Source | 1,065,000Source | 2,975,000Source | 497,000Source | 3,310,000Source | 478,000Source | 157,870,000Source | — | — |
| Interest ExpenseUSD | — | — | — | — | — | 28,345Source | — | 26,974Source | — | 96,242Source | 36,909Source |
| Investment Income, InterestUSD | — | — | — | 197,278Source | — | 18,080Source | — | 78,971Source | — | 1,578,042Source | 3,843,271Source |
| Operating Costs and ExpensesUSD | — | — | — | 212,951Source | — | 374,857Source | — | 246,600Source | — | 1,649,106Source | 3,173,826Source |
| Operating ExpensesUSD | — | — | 152,594,000Source | 1,298,000Source | 4,224,000Source | 999,000Source | 4,576,000Source | 665,000Source | 160,416,000Source | — | — |
| Other Cost and Expense, OperatingUSD | — | — | — | — | — | 61,214Source | — | 131,693Source | — | 485,144Source | — |
| Other ExpensesUSD | — | — | — | — | — | — | — | — | — | — | 30,000,000Source |
| Research and Development ExpenseUSD | — | — | 1,143,000Source | 233,000Source | 1,249,000Source | 502,000Source | 1,266,000Source | 187,000Source | 2,546,000Source | — | — |
| Nonoperating Income (Expense) | — | — | — | — | —Source | —Source | — | — | — | — | — |
Offerings
Registration 333-290995
Filing attachments
smnr-ex99_1.htm · 8-K · 2026-07-07
EX-99.1 2 smnr-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 FOR IMMEDIATE RELEASE July 7, 2026 Semnur Pharmaceuticals, Inc., a Majority-Owned Subsidiary of Scilex Holding Company, Announces Signing of Binding Term Sheet for Proposed $100 Million Strategic Investment from iHolding Group LLP PALO ALTO, CALIFORNIA - July 7, 2026 (GLOBE NEWSWIRE) - Semnur Pharmaceuticals, Inc. (“Semnur” or the “Company”) (OTC: SMNR), a clinical late-stage specialty pharmaceutical company focused on the developme…
Read attachment ↗